Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
3.06
Jun 26 • 04:00PM ET Dollar change+0.01 Percentage change(0.33%)
Jun 25, 9:35 AMCo-Diagnostics' Vector Smart mosquito surveillance division now serves mosquito abatement districts in 21 U.S. states
Index
-
P/E
-
EPS (ttm)
-28.01
Insider Own
5.35%
Shs Outstand
3.60M
Perf Week
-9.20%
Market Cap
11.28M
Forward P/E
-
EPS next Y
-
Insider Trans
0.00%
Shs Float
3.49M
Perf Month
-58.08%
Enterprise Value
5.08M
PEG
-
EPS next Q
-
Inst Own
7.78%
Perf Quarter
51.49%
Income
-48.50M
P/S
22.12
EPS this Y
-
Inst Trans
3.35%
Perf Half Y
-58.40%
Sales
0.51M
P/B
0.69
EPS next Y
-
ROA
-126.56%
Perf YTD
-39.50%
Book/sh
4.45
P/C
1.37
EPS next 5Y
-
ROE
-151.66%
52W High
46.50 -93.42%
Perf Year
-61.78%
Cash/sh
2.23
P/FCF
-
EPS past 3/5Y
-37.47% -
ROIC
-281.74%
52W Low
1.26 142.86%
Perf 3Y
-90.81%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
-76.97% -64.54%
Gross Margin
-187.30%
Volatility
13.45% 26.11%
Perf 5Y
-98.81%
Dividend TTM
-
EV/Sales
9.96
EPS Y/Y TTM
18.03%
Oper. Margin
-6255.15%
ATR (14)
1.07
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
2.09
Sales Y/Y TTM
-9.46%
Profit Margin
-9438.49%
RSI (14)
43.55
Dividend Gr. 3/5Y
- -
Current Ratio
2.28
EPS Q/Q
42.48%
SMA20
-32.95%
Beta
2.93
Payout
-
Debt/Eq
0.13
Sales Q/Q
190.30%
SMA50
-10.05%
Rel Volume
0.02
Prev Close
3.05
Employees
115
LT Debt/Eq
0.07
SMA200
-50.50%
Avg Volume
5.58M
Price
3.06
IPO
Jul 12, 2017
Option/Short
No / Yes
Trades
Volume
100,302
Change
0.33%
Jun-25-26 09:00AM
Jun-18-26 09:05AM
Jun-11-26 09:00AM
Jun-02-26 09:00AM
May-26-26 01:00PM
09:00AM Loading…
09:00AM
May-19-26 10:54PM
10:34AM
May-15-26 08:30AM
01:02AM
May-14-26 04:01PM
May-11-26 05:43AM
May-08-26 09:00AM
Apr-16-26 09:00AM
Apr-14-26 09:00AM
09:00AM Loading…
Apr-09-26 09:00AM
Apr-02-26 09:00AM
Apr-01-26 08:30AM
Mar-31-26 11:02PM
04:01PM
Mar-25-26 08:00AM
Mar-20-26 03:30PM
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.
ChairmanMr. Dwight H. Egan
PresidentMr. Richard David Abbott
CFO & Company SecretaryMr. Brian L. Brown CPA
Chief Operating OfficerMr. David Nielsen
Vice President of Finance & AccountingMr. Dan Bohrer CPA